Results to your Biomarker
Matching services
Biomonitoring
In the field of human biomonitoring (HBM), we offer a comprehensive range of LC-MS and GC-MS-based methods tailored for the precise quantitative determination of environmental chemicals and their specific metabolites in various biological matrices, including urine, serum, plasma and saliva. Our commitment to accuracy and precision is what sets us apart. Our methods are routinely used in biomonitoring campaigns, allowing us to comprehensively assess both occupational and non-occupational exposures to environmental chemicals. At the heart of our services is a commitment to improving understanding of how these substances interact with the human body, ultimately promoting a healthier and more sustainable future.
Bioanalysis of Cannabinoids
At the forefront of scientific development, ABF is leading the way with innovative methods for the accurate analysis of cannabis and cannabinoids. Risk assessment of these new products using appropriate biomarkers is becoming increasingly important, particularly for pharmacokinetic (PK) and toxicokinetic (TK) studies, exposure assessment and risk evaluation. Our cannabinoid panel encompasses THC, CBD, CBG and THCV in plasma. The bioanalytical method runs routinely according to GCP and GLP as part of our ISO 17025-accredited method portfolio in PK and TK studies. Our aim is to support you responsibly in the introduction of new products. ABF is your partner for reliable and innovative cannabinoid bioanalysis.
Tobacco Harm Reduction
With over four decades of experience, ABF is a globally leading expert in bioanalysis for biomarkers of exposure related to tobacco and new emerging nicotine products, trusted by clients worldwide. We have analyzed biological samples for hundreds of (non-)clinical studies, applying the largest set of fully validated bioanalytical methods in the field of tobacco harm reduction. Our methods are regularly applied in exposure and nicotine PK studies, supporting regulatory product submissions especially in the US under FDA CTP's PMTA and MRTPA. We continuously expand our portfolio by developing and validating bioanalytical methods for new biomarkers of exposure and biomarkers of potential harm, staying at the forefront of scientific advancements. At ABF, we are committed to help our clients responsibly launch new nicotine products in the marketplace. Choose ABF for reliable and cutting-edge bioanalysis services in the field of tobacco harm reduction.